Executive Summary

Today, new knowledge in pathology drives a development of more targeted drugs. This 500 page report structures and analyzes the new generation of targeted therapeutics for the treatment of cancer. It is BioSeeker's most comprehensive report on emerging cancer therapeutics so far.  

In the field of cancer therapeutics, cytotoxic drugs will be replaced with treatments based on a biological approach. Hopefully these new therapies will take over the market not only by increasing the efficacy, but also by significantly decreasing the devastating and troublesome side effects elicted by chemotherapy. Bioseeker along with other analysts believes that this will soon have a substantial impact on the market. Rituxan is one obvious example of this transition. 

Novel therapeutic strategies include immunotherapy, vascular targeting, antisens, gene therapy, targeted therapeutics and apototic induction have been studied to reveal mainly industry progress but as well key scientific breakthroughs. Several hundreds of therapeutic candidates are competing in this enviroment and many of them will never succeed, whereas a few will turn out to be the big winners. 

This Highlight Report will provide you with an update on the early failure of drugs in anti-angiogenesis such as Avastin, Erbitux, SU5416, Marimastat, Endostatin and Angiostatin. The report will also provide you with an update on the recent advances on vascular targeting, the next approach to inhibit angiogenesis. The progress made in gene therapy where only limited number of companies is in late stage clinical trials is also presented. Updates are also given for the development that occurs in the antisense technology, where the drug Affinitek recently failed to prolong the life of lung cancer patients. However, several big drug companies have partnered with antisense drug developers in the hope that the technology might prove succesful. Furthermore, the report gives an overview on the most recent advancements made by pharmaceutical companies in their choice of therapeutic targets, to induce the apoptotic pathways. A field where a number of antisense related companies play an important role, most notorius the antisense agent Genasense, which targets Bcl-2. 

There are several novel strategies emerging and BioSeeker Group is following this development carefully. In this report, we have compiled new knowledge and assessed the achievements during the latest years of development. Additionally, information from several important recent cancer meetings (ASCO 2003, AACR 2003, ASH 2002, Visiongain's Cancer drugs 2003 and Barnett International's Emerging Cancer Therapeutics) is also included in the analysis. The latest patents filings (PCT) in this field have also been analyzed to broaden the prespective on anticancer R&D activity. Other subjects that included are Endpoints and markers of efficacy, Patient populations, Regulatory issues, Adjuvant and boost regime strategies. 

Through the continuous surveillance of more than 10,000 life science companies worldwide, BioSeeker Group analyses activities in biotechnology and pharmaceutical industry. Sophisticated information management in combination with highly educated analysts with extensive experience in business intelligence builds a strong platform for producing valuable analytical documents. 

Our Highlight Reports are produced to enable our customers to be updated on the progress within different sectors of the pharmaceutical and biotechnology industry, and will give you access to achievements and novel breakthroughs during the latest years of activities. Apart from the pharma industry itself, this report is of value to investors, science incubators, investigators, contract research organizations or any other types of organization with an interest in cancer therapeutics. 

Release date: Dec 05, 2003 

 Publisher: BioSeeker 2003 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker_2003.html#a454